Savara (SVRA) announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM. The manuscript will appear in the online version of the publication. Following the online publication in NEJM, the manuscript will be available on the Congresses & Publications page of the company’s corporate website.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA: